Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Newly Diagnosed Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center

被引：0
|
作者：
Masarova, Lucia [1 ]
Kantarjian, Hagop [1 ]
Verstovsek, Srdan [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-031
引用
收藏
页码：S20 / S21
页数：2
相关论文
共 50 条
  • [41] THE HIGH MOLECULAR RISK (HMR) STATUS DOES NOT ACCURATELY PREDICT POOR OUTCOME IN PATIENTS WITH POST-ESSENTIAL THROMBOCYTHEMIA AND POST-POLYCYTHEMIA VERA MYELOFIBROSIS
    Guglielmelli, P.
    Coltro, G.
    Rotunno, G.
    Romagnoli, S.
    Maccari, C.
    Paoli, C.
    Gesullo, F.
    Loscocco, G. G.
    Vannucchi, A. M.
    HAEMATOLOGICA, 2021, 106 (10) : 82 - 82
  • [42] Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Apostolidou, Effrosyni
    Kantarjian, Hagop
    Thomas, Deborah
    Burger, Ian
    Borthakur, Gautam
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 281 - 284
  • [43] An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
    Barosi, Giovanni
    Agarwal, Mohan
    Zweegman, Sonja
    Willenbacher, Wolfgang
    Pakstyte, Sima
    Raymakers, Reinier
    Cantoni, Nathan
    Modi, Ankur
    Khan, Mahmudul
    Perez, Jose Ricardo
    Hasselbalch, Hans
    Vargas Viveros, Jose Pablo
    Linardi, Camila C. G.
    Gisslinger, Heinz
    Daumas Gabriel, Adelmo Henrique
    Palandri, Francesca
    Lavie, David
    Harrison, Claire N.
    BLOOD, 2012, 120 (21)
  • [44] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
    Xin Du
    Daobin Zhou
    Frontiers of Medicine, 2016, 10 : 437 - 443
  • [45] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
    Xin Du
    Daobin Zhou
    Frontiers of Medicine, 2016, 10 (04) : 437 - 443
  • [46] Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population
    Du, Xin
    Zhou, Daobin
    FRONTIERS OF MEDICINE, 2016, 10 (04) : 437 - 443
  • [47] The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
    McMullin, Mary Frances
    Harrison, Claire N.
    Niederwieser, Dietger
    Demuynck, Hilde
    Jakel, Nadja
    Sirulnik, Andres
    McQuity, Mari
    Stalbovskaya, Viktoriya
    Recher, Christian
    Theunissen, Koen
    Gisslinger, Heinz
    Kiladjian, Jean-Jacques
    Al-Ali, Haifa-Kathrin
    BLOOD, 2012, 120 (21)
  • [48] A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
    Passamonti, Francesco
    Rumi, Elisa
    Caramella, Marianna
    Elena, Chiara
    Arcaini, Luca
    Boveri, Emanuela
    Del Curto, Cecilia
    Pietra, Daniela
    Vanelli, Laura
    Bernasconi, Paolo
    Pascutto, Cristiana
    Cazzola, Mario
    Morra, Enrica
    Lazzarino, Mario
    BLOOD, 2008, 111 (07) : 3383 - 3387
  • [49] A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
    Passamonti, Francesco F.
    Rumi, Elisa E.
    Caramella, Marianna M.
    Elena, Chiara C.
    Arcaini, Luca L.
    Boveri, Emanuela E.
    Del Curto, Cecilia C.
    Pietra, Daniela D.
    Vanelli, Laura L.
    Pascutto, Cristiand C.
    Cazzola, Mario M.
    Morra, Enrica E.
    Lazzarino, Mario M.
    BLOOD, 2007, 110 (11) : 750A - 751A
  • [50] Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)
    Pemmaraju, Naveen
    Carter, Bing Z.
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Bose, Prithviraj
    Pierce, Sherry
    Zhou, Lingsha
    Estrov, Zeev
    Tuttle, Carla Kay
    Salinas, Karina
    Mak, Po Yee
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
12345